Some DMARD treatments, such as hydroxychloroquine, anti-TNFα, and IL-6 inhibitors, have been employed during the COVID-19 pandemic to reduce the systemic inflammation associated with severe disease and are being studied for the prevention and/or treatment of COVID-19 and its complications (6–9). The gene discussed is TNF; the disease is COVID-19.